Literature DB >> 24723200

Pediatric ulcerative colitis: a practical guide to management.

Brian P Regan1, Athos Bousvaros.   

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract of unknown etiology that frequently presents in the pediatric population. The evaluation of pediatric UC involves excluding infection, and a colonoscopy that documents the clinical and histologic features of chronic colitis. Initial management of mild UC is typically with mesalamine therapy for induction and maintenance. Moderate UC is often initially treated with oral prednisone. Depending on disease severity and response to prednisone, maintenance options include mesalamine, mercaptopurine, azathioprine, infliximab, or adalimumab. Severe UC is typically treated with intravenous corticosteroids. Corticosteroid nonresponders should either undergo a colectomy or be treated with second-line medical rescue therapy (infliximab or calcineurin inhibitors). The severe UC patients who respond to medical rescue therapy can be maintained on infliximab or thiopurine, but 1-year remission rates for such patients are under 50 %. These medications are discussed in detail along with the initial work-up and a treatment algorithm.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24723200     DOI: 10.1007/s40272-014-0070-8

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  75 in total

1.  Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

Authors:  J H BARON; A M CONNELL; T G KANAGHINIS; J E LENNARD-JONES; A F JONES
Journal:  Br Med J       Date:  1962-08-18

2.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

3.  Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.

Authors:  Haruhiko Ogata; Jun Kato; Fumihito Hirai; Nobuyuki Hida; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Koyanagi; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

4.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.

Authors:  C Cuffari; S Hunt; T Bayless
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

5.  Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.

Authors:  Ivanka Curkovic; Katharina M Rentsch; Pascal Frei; Michael Fried; Gerhard Rogler; Gerd A Kullak-Ublick; Alexander Jetter
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

6.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

Authors:  E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

Review 7.  Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.

Authors:  M A Peppercorn
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

8.  Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.

Authors:  J Doering; B Begue; M J Lentze; F Rieux-Laucat; O Goulet; J Schmitz; N Cerf-Bensussan; F M Ruemmele
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.

Authors:  Athos Bousvaros; Donald A Antonioli; Richard B Colletti; Marla C Dubinsky; Jonathan N Glickman; Benjamin D Gold; Anne M Griffiths; Gareth P Jevon; Leslie M Higuchi; Jeffrey S Hyams; Barbara S Kirschner; Subra Kugathasan; Robert N Baldassano; Pierre A Russo
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-05       Impact factor: 2.839

10.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

View more
  7 in total

1.  Use of Electronic Health Record Tools to Facilitate and Audit Infliximab Prescribing.

Authors:  Bethany R Sharpless; Fernando Del Rosario; Zarela Molle-Rios; Elora Hilmas
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

Review 2.  Environmental Enteric Dysfunction in Children.

Authors:  Sana Syed; Asad Ali; Christopher Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-07       Impact factor: 2.839

3.  Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.

Authors:  Yetrib Hathout; Laurie S Conklin; Haeri Seol; Heather Gordish-Dressman; Kristy J Brown; Lauren P Morgenroth; Kanneboyina Nagaraju; Christopher R Heier; Jesse M Damsker; John N van den Anker; Erik Henricson; Paula R Clemens; Jean K Mah; Craig McDonald; Eric P Hoffman
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

4.  Shen-Ling-Bai-Zhu-San for ulcerative colitis: Protocol for a systematic review and meta-analysis.

Authors:  Long Yang; Yuanyuan Song; Pei Jin; Yueyang Liu; Yue Wang; Huixia Qiao; Yahui Huang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

5.  Traditional Chinese medicine for mild-to-moderate ulcerative colitis: Protocol for a network meta-analysis of randomized controlled trials.

Authors:  Zhaofeng Shen; Qing Zhou; Yingjun Ni; Weiming He; Hong Shen; Lei Zhu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

6.  Chinese herbal medicines in the treatment of ulcerative colitis: a review.

Authors:  Xuan Zhang; Lin Zhang; Jacky C P Chan; Xihong Wang; Chenchen Zhao; Ying Xu; Weifeng Xiong; Wai Chak Chung; Feng Liang; Xu Wang; Jiangxia Miao; Zhaoxiang Bian
Journal:  Chin Med       Date:  2022-04-04       Impact factor: 5.455

7.  Effects of herb-partitioned moxibustion for ulcerative colitis: A protocol for systematic review and meta-analysis.

Authors:  Xiao Yan; Fengjun Ma; Yanpu Yu; Dongqing Du; Zhilei Wang; Chen Chen; Xiaobin Zhang; Xiao Sun; Zhibin Dong; Yuxia Ma; Yuning Ma
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.